Improved focus on test quality and reliability to drive the penetration of the home diagnostics market

Home diagnosis, also called in-vitro diagnosis or self-diagnosis test, is a test that detects medical conditions and illnesses at home from samples collected from the human body such as blood, urine, and saliva. Home diagnostics are popular among patients because these tests are quick, cost-effective, and highly confidential.

The emergence of personalized medicine to become a game changer for market growth

Increasing awareness of healthcare is increasing the adoption of customized medicines and home diagnostics among consumers. Sensing the needs of end users, players operating in the global home diagnostics market are focused on improving efficiency, accuracy, reliability, and convenience. Today, investment is constantly shifting to incorporating advanced technology into the manufacture of home diagnostics. 

With the adoption of a new era of wearable technology, artificial intelligence (AI), and the Internet of Things (IoT), companies operating in the global market are focused on improving the overall performance and functionality of home diagnostics. I will. For example, Abbott Technologies and Siemens Healthcare are currently planning to introduce several different types of digital home diagnostics that can be integrated with a new era of smartphones. This will be a future trend in the global market in the coming years.
The surprising increase in the incidence of lifestyle-related diseases and causes of death due to chronic health disorders is affecting health and governance agencies to shift their focus to improving the quality of diagnostic services.

The accuracy and accuracy of the results provided by these tests plays an important role in the performance of home diagnostics, as home diagnostics help patients detect illness without specialized medical assistance. In light of the widespread use of home diagnostics, governing bodies around the world impose strict rules and regulations to ensure the quality and reliability of home diagnostics sold worldwide. Home diagnostic manufacturers must comply with Section 510 (k) of the Food, Drug, and Cosmetic Act and obtain premarket approval application (PMA) approval established by the FDA to enter the US home diagnostic market. There is.

In addition, the European Union imposes regulations that all stakeholders in the home diagnostics market must comply with, such as the Medical Device Regulation 2017/745 / EU and the In Vitro Diagnostic Medical Device Regulation 2017/746 / EU. Strict quality control regulations and labeling requirements can impact the growth prospects of the home diagnostics market, as it can make it difficult for market players to reduce manufacturing costs.

Market players focusing on aggressive growth strategies

Leading market players in the home diagnostics market are adopting joint strategies to expand their presence in the highly competitive environment of the global diagnostics industry. For example, Quidel Corportation recently acquired Alere Triage® assets such as the cardiovascular and toxicology business and the type B natriuretic peptide (BNP) assay business to expand its innovative diagnostic portfolio. Roche Holding AG, another major stakeholder in the home diagnostics market, has entered into a strategic partnership with GE Healthcare to provide in vivo and in vitro data-driven diagnostics, including tests that can be used at home by critical care patients. I will.
Market players in the home diagnostics market featured in the report include Abbott Laboratories, ACON Laboratories, BTNX, Arkray, and Asuretech (Hangzhou). Ltd., Becton Dickinson & Company, Bionime Corporation, Roche Holding AG, Quidel Corporation, and True Diagnostics Inc.